Eli Lilly In Talks To Buy ImClone
Eli Lilly is in advanced talks to buy ImClone Systems for $70 a share, topping the sweetened $62 per share offer from Bristol-Myers Squibb. The deal would value ImClone, which makes the cancer drug Erbitux, at about $6.1 billion. (WSJ Health Blog)












No Comments Yet
You can be the first to comment!
Leave a comment